LIMN (Liminatus Pharma, Inc. Class A Common Stock) Stock Analysis - Financials

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded Healthcare sector company. As of May 21, 2026, LIMN trades at $0.29 with a market cap of $8.40M and a P/E ratio of -0.43. LIMN moved -1.21% today. Year to date, LIMN is -72.50%; over the trailing twelve months it is -97.02%. Its 52-week range spans $0.16 to $33.66. Rallies surfaces LIMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are LIMN's key financials?

LIMN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LIMN recently traded at $0.29. Market cap is $8.40M. P/E ratio is -0.43. Revenue is $0.

LIMN Key Metrics

Key financial metrics for LIMN
MetricValue
Price$0.29
Market Cap$8.40M
P/E Ratio-0.43
EPS$-0.43
Dividend Yield0.00%
52-Week High$33.66
52-Week Low$0.16
Volume83.47M
Avg Volume0
Revenue (TTM)$0
Net Income$-10.21M
Gross Margin0.00%

LIMN Annual Financials

YearRevenueNet IncomeEPS
2025$0$-10.21M$-0.43

Latest LIMN News

LIMN Analyst Consensus

LIMN analyst coverage data. Average price target: $0.00.

Common questions about LIMN

What are LIMN's key financials?
LIMN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LIMN recently traded at $0.29. Market cap is $8.40M. P/E ratio is -0.43. Revenue is $0.
Is LIMN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIMN. It does not provide personalized investment advice.
LIMN

LIMN